Latest From Storm Therapeutics
An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.
Cambridge Innovation Capital completes £150m fundraising to give it more firepower to reinforce Cambridge, UK’s pre-eminent status as Europe’s leading life sciences and tech hub.
Repeat antibiotic entrepreneurs raised $33m to launch Qpex with assets from The Medicines Co. Also, Taiho increases VC fund to $300m and TP Therapeutics raises $80m.
Keith Blundy, CEO of STORM Therapeutics, discusses the company’s founding and upcoming milestones.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Storm Therapeutics
- Senior Management
- Contact Info
Phone: 1223 804174
Babraham Research Campus
Cambridge, CB22 3AT
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.